Mixed options sentiment in Novo Nordisk (NVO), with shares up $1.85, or 4.0%, near $48.22. Options volume roughly in line with average with 31k ...

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The ...

Lexicon Pharmaceuticals (LXRX) announced the publication of preclinical data validating Acyl-CoA Synthetase 5 as a target for obesity and chronic ...

A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...

Lexicon Pharmaceuticals, Inc. currently offers three late-stage assets Zynquista, Inpefa & Pilavapadin. Learn more about LXRX ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal diabetes trials of an asset that it previously saw primarily as an obesity ...

A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...

Destinations International (DI), the world’s leading association for destination organizations, will proudly mark World Tourism Lexicon Day tomorrow, November 13, with release of the 2025 Tourism ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Pfizer has won the ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech declaring Novo's offer "superior"—even though it has already inked an ...

Drugmaker Pfizer PFE1.78%increase; green up pointing triangle on Friday sued obesity-drug developer Metsera and Novo Nordisk NOVO.B 3.31%increase; green up pointing triangle, seeking to block Metsera ...